MGNX · XBRL financial data

Macrogenics financial statements, every fiscal year

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MGNX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	105	77	152	59	150	150
Cost of goods and services sold	0	3	3	1	1	0
Research and development	193	215	207	167	177	147
General and administrative	43	63	59	52	71	39
Operating income (loss)	(131)	(203)	(121)	(168)	(111)	(73)
Interest expense	—	0	0	1	1	9
Other income (expense)	1	1	2	10	9	6
Income tax expense (benefit)	0	0	0	0	1	(1)
Net income (loss)	(130)	(202)	(120)	(9)	(67)	(75)
Earnings per share, basic USD per share	(2.47)	(3.37)	(1.95)	(0.15)	(1.07)	(1.18)
Earnings per share, diluted USD per share	(2.47)	(3.37)	(1.95)	(0.15)	(1.07)	(1.18)
Weighted average shares, basic millions of shares	52	60	61	62	63	63
Weighted average shares, diluted millions of shares	52	60	61	62	63	63

Fiscal years (MGNX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	181	123	109	101	183	57
Accounts receivable	23	10	56	10	4	13
Inventory	0	4	1	1	0	8
Prepaid and other current assets	17	21	10	10	12	7
Total current assets	313	280	222	251	217	220
Property and equipment, net	42	38	30	22	18	13
Right-of-use asset	19	17	27	24	25	23
Total assets	379	335	280	298	262	257
Accounts payable	8	16	5	6	5	5
Accrued liabilities	34	34	29	24	29	22
Total current liabilities	51	75	49	56	56	43
Lease liability, non-current	25	21	30	30	33	32
Total liabilities	83	96	138	146	146	201
Accumulated deficit	(772)	(974)	(1,094)	(1,103)	(1,170)	(1,244)
Total stockholders' equity	296	240	142	153	116	56
Total liabilities and equity	379	335	280	298	262	257
Common shares outstanding (cover page) millions of shares	56	61	62	62	63	64

Fiscal years (MGNX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(130)	(202)	(120)	(9)	(67)	(75)
Stock-based compensation	21	23	20	18	29	14
Depreciation and amortization	12	11	12	10	8	7
Net cash from operating activities	(112)	(144)	(87)	(78)	(68)	(81)
Purchases of property and equipment	6	6	4	2	4	2
Net cash from investing activities	(8)	(37)	71	(80)	149	(114)
Proceeds from issuing common stock	170	118	1	1	0	0
Net cash from financing activities	174	123	2	150	1	70
Net change in cash	55	(58)	(15)	(8)	82	(126)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Macrogenics	114	33	(41)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	32	0	(18)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2.8	0.4	(5.2)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43	29	(17)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Oncolytics Biotech	4.1	not reported	(8.1)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	16	0.7	(22)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	110	not reported	(4.5)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15	not reported	(0.2)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23	not reported	(30)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.